BioAtla, Inc. (BCAB)
- Previous Close
2.0300 - Open
2.0700 - Bid 2.0300 x 100
- Ask 2.1400 x 100
- Day's Range
1.9700 - 2.2091 - 52 Week Range
1.1400 - 4.0200 - Volume
3,407,853 - Avg. Volume
1,073,444 - Market Cap (intraday)
100.973M - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
-- - EPS (TTM)
-2.1700 - Earnings Date Nov 5, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.75
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.
www.bioatla.comRecent News: BCAB
View More
Performance Overview: BCAB
Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BCAB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BCAB
View MoreValuation Measures
Market Cap
98.12M
Enterprise Value
38.12M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.13
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-55.37%
Return on Equity (ttm)
-134.14%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-104.56M
Diluted EPS (ttm)
-2.1700
Balance Sheet and Cash Flow
Total Cash (mrq)
61.66M
Total Debt/Equity (mrq)
5.30%
Levered Free Cash Flow (ttm)
-71.12M
Research Analysis: BCAB
View MoreCompany Insights: BCAB
BCAB does not have Company Insights
Research Reports: BCAB
View MoreDaily – Vickers Top Buyers & Sellers for 12/21/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/31/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 06/10/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/01/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.